Data updated: Mar 10, 2026
VITEKTA
ELVITEGRAVIR
Approved 2014-09-24
1
Indication
--
Phase 3 Trials
11
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2014-09-24
- Routes
- ORAL
- Dosage Forms
- TABLET
VITEKTA Approval History
Loading approval history...
What VITEKTA Treats
1 FDA approvalsOriginally approved for its first indication in 2014 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VITEKTA FDA Label Details
ProVITEKTA Patents & Exclusivity
Latest Patent: Apr 2027
Patents (24 active)
US7635704*PED
Expires Apr 26, 2027
US8981103*PED
Expires Apr 26, 2027
US7176220*PED
Expires Feb 27, 2027
US7635704
Expires Oct 26, 2026
US8981103
Expires Oct 26, 2026
US7176220
Expires Aug 27, 2026
+ 14 more patents
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.